Deltec Asset Management LLC decreased its position in Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) by 50.0% during the second quarter, Holdings Channel reports. The firm owned 20,000 shares of the biopharmaceutical company’s stock after selling 20,000 shares during the period. Deltec Asset Management LLC’s holdings in Keryx Biopharmaceuticals were worth $132,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Norges Bank bought a new position in Keryx Biopharmaceuticals during the fourth quarter worth approximately $9,150,000. Geode Capital Management LLC boosted its stake in shares of Keryx Biopharmaceuticals by 5.4% in the first quarter. Geode Capital Management LLC now owns 699,895 shares of the biopharmaceutical company’s stock worth $3,268,000 after buying an additional 36,038 shares during the period. Royce & Associates LP boosted its stake in shares of Keryx Biopharmaceuticals by 32.2% in the first quarter. Royce & Associates LP now owns 451,725 shares of the biopharmaceutical company’s stock worth $2,110,000 after buying an additional 110,000 shares during the period. Finally, Metropolitan Life Insurance Co. NY boosted its stake in shares of Keryx Biopharmaceuticals by 1.2% in the first quarter. Metropolitan Life Insurance Co. NY now owns 75,108 shares of the biopharmaceutical company’s stock worth $351,000 after buying an additional 874 shares during the period. 61.13% of the stock is currently owned by institutional investors and hedge funds.

Shares of Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) traded up 4.87% on Thursday, reaching $5.17. 1,396,157 shares of the company’s stock traded hands. The firm’s market cap is $547.48 million. Keryx Biopharmaceuticals Inc. has a 12-month low of $2.80 and a 12-month high of $7.80. The stock has a 50-day moving average of $4.47 and a 200 day moving average of $5.40.

Keryx Biopharmaceuticals (NASDAQ:KERX) last announced its quarterly earnings results on Monday, August 1st. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.28) by $0.14. Keryx Biopharmaceuticals had a negative return on equity of 172.04% and a negative net margin of 590.50%. The business earned $9.30 million during the quarter, compared to the consensus estimate of $8.60 million. During the same quarter in the prior year, the firm posted ($0.26) EPS. The company’s revenue for the quarter was up 272.0% on a year-over-year basis. On average, equities research analysts expect that Keryx Biopharmaceuticals Inc. will post ($1.24) earnings per share for the current year.

A number of equities research analysts have recently issued reports on KERX shares. Maxim Group reaffirmed a “buy” rating and issued a $9.00 price objective (up previously from $7.00) on shares of Keryx Biopharmaceuticals in a research note on Friday, July 8th. Zacks Investment Research raised shares of Keryx Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $8.00 price objective for the company in a research note on Wednesday, July 13th. FBR & Co reaffirmed a “buy” rating and issued a $13.00 price objective on shares of Keryx Biopharmaceuticals in a research note on Monday, July 25th. Stifel Nicolaus cut shares of Keryx Biopharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, August 2nd. Finally, Brean Capital cut shares of Keryx Biopharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, August 2nd. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and three have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $7.75.

In related news, CFO Scott A. Holmes sold 4,935 shares of the business’s stock in a transaction on Friday, July 29th. The shares were sold at an average price of $7.36, for a total value of $36,321.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 3.08% of the stock is currently owned by corporate insiders.

About Keryx Biopharmaceuticals

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. The Company’s product Auryxia (ferric citrate), also known as Riona in Japan and Fexeric in Europe, is an oral, absorbable iron-based compound, which is indicated for the control of serum phosphorus levels in patients with chronic kidney disease (CKD), on dialysis.

5 Day Chart for NASDAQ:KERX

Want to see what other hedge funds are holding KERX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Keryx Biopharmaceuticals Inc. (NASDAQ:KERX).

Receive News & Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.